[Influences of tumor necrosis factor-alpha on protein metabolism and cell-cycle kinetics in malignant tumor].
Sprague-Dawley rats, subcutaneously inoculated with Walker 256 carcinosarcoma, were injected intraperitoneally with recombinant human TNF-alpha at a dose of 4.75 x 10(6) U/kg for 3 consecutive days. Protein metabolism and cell-cycle kinetics of the tumor were studied. The results showed a significant decrease in tumor volume and weight in comparison with control. TNF resulted in significant decrease in tumor protein fractional synthesis rate (25.3% +/- 3.5%.d-1 versus control 42.9% +/- 2.7%.d-1, P < 0.01), protein synthesis (0.20 +/- 0.05 g/d versus control 1.14 +/- 0.20 g/d, P < 0.001) and fractional growth rate (24.3% +/- 2.1%.d-1 versus control 35.8% +/- 2.3%.d-1, P < 0.01), but no change of tumor protein fractional degradation rate. TNF also resulted in remarkable decline in labelling index (30.8% +/- 4.2% versus control 44.7% +/- 4.2%, P < 0.01) and G1 phase increase (6.0% +/- 1.3% versus control 12.2% +/- 2.5%, P < 0.01) of tumor cells, 6 hours after injection of bromodeoxyuridine, by flow cytometry. The results indicate that TNF inhibits tumor growth as a result of decreases in tumor cell DNA and protein syntheses.
Ye
S L
SL
Liver Cancer Institute, Shanghai Medical University.
Tang
Z Y
ZY
Bistrian
B R
BR
D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy / Q000378:metabolism*; D002453:Cell Cycle / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D007274:Injections, Intraperitoneal; D008297:Male; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha